Close up of honeycomb and several bees
Asset 1

Private equity

We are the mid-market deal experts. We advise on private equity deals of all levels of sophistication and speed, with an international team that is technically astute, highly commercial and practical. We know how to deliver a competitive bid in an auction, provide sound solutions, and close deals on time.

We understand the commercial drivers of PE investors and combine smart insights with some deep sector knowledge. We advise on deals across many sectors, but are particularly adept at working with our technology colleagues on some of the most high-profile and innovative tech, life sciences and healthcare deals in the market.

Our deals are regularly multi-jurisdictional, complex and headline-grabbing. Clients include private equity funds, portfolio companies and management teams, giving us a 360 degree view on a buyout and an ability to advise on risk-based decisions typically considered by investment committees. We will negotiate with a strategic mindsight rather than point-score for the sake of it. When acting for PE funds, we are skilled at advising on buyout transactions from founders. Our work for management teams means we know how to get a deal across the line with a successful outcome for all parties. Working for management we frequently advise at the upper end of the buyout market.

In the context of our wider corporate practice, our M&A market experience, coupled with our long-established venture capital and private wealth offerings, gives us a unique and compelling 'private capital' model. This ranges from fund formation and seed investment, through to growth capital and buyout transactions, and exits by way of secondary buyout, trade sales or IPOs.

Private equity

Advising Mecsia and Rockpool on Mecsia sale to Synova

13 March 2024

by multiple authors

Click here to find out more
Private equity

Advising Bridgepoint on its investment in Identicare

5 March 2024

by Emma Danks and Jonny Bethell

Click here to find out more
Careers

Taylor Wessing adds prominent Investment Fund Formation Partner in London

4 March 2024

by Edward Waldron and Shervin Shameli

Click here to find out more
Private equity

Advising Essential Pharma on its acquisition of European rights to Colobreathe®

12 January 2024

by multiple authors

Click here to find out more

Our team

Our international private equity team is a prominent force in the market for mid-market leveraged domestic and cross-border transactions. We act for large number of private equity sponsors, investee companies, management teams and debt providers and work across a range of industries and deal sizes. Our experience in representing a large number of UK and international private equity houses, coupled with our market-leading venture capital and private wealth offering allows us to deliver what we believe to be a unique "private capital" model. 

Tools and online services

Related events

There are no upcoming events